NIBRT has presented results of its “2016 Trends in Biopharma Survey”. The survey assesses the key trends in biopharma pipelines, manufacturing technologies and staff development.
Key findings include:
- 38
- Overall, 69
- There is a strong consensus that monoclonal antibodies (mAb) are the dominant therapy for the immediate future. However, product pipelines will diversify in a 5-10 year period with products such as cell and gene therapies becoming increasingly important. A key challenge will be establishing cost effective manufacturing solutions for these newer therapies. Two thirds of respondents agreed that biosimilars would have a major impact on the market.
- With respect to biopharma manufacturing, 67
- Recruitment and development of talent is seen as a key threat to the future growth of the sector.
In particular, 57 - Overall access to skilled staff, manufacturing models for new therapies and cost issues were included as the main challenges to the growth of the sector. Key opportunities identified included cell therapies, gene therapies, biosimilars and standardised platform based, cost effective
